The role of microbiota in epithelial ovarian cancer: a scoping review

Objective: The objective of this review was to examine the comprehensive role of microbiota in epithelial ovarian carcinogenesis. Methods: A scoping review method was used, and relevant databases were searched using combinations of key terms. Human and animal studies were selected that met inclusion criteria and critical appraisal tools were used to assess study quality. Results: A total of 10 international studies (human n = 8; animal n = 2) were included with total samples sizes varying from 16 to 580. Mean/median ages of women with epithelial ovarian cancer (EOC) were 50.5 to 66 years, and controls were 47.3 to 56 years. Compared to the ovaries and fallopian tubes of women without disease, tissue collected from women with EOC were characterized by differing proportions of bacterial phyla including Actinobacteria, Bacteroidetes, Chlamydiae, Firmicutes, and Proteobacteria. Intestinal depletions and reduced diversity of genera Lactobacillus accelerated ovarian tumor growth in animal models. Cytomegalovirus and human papillomavirus types 6, 16, 18, and 45 had a significantly higher prevalence in women with disease and represented up to 70% of cases with high-grade serous ovarian carcinoma. Colonized bacteria were detected in fallopian tubes, peritoneal fluid, and ovarian tissue similar to that of commensal GI tract and vaginal bacteria. Conclusion: The EOC microenvironment harbors diverse microbes. Due to the heterogeneity of microbiota identified between studies, additional research is needed to reconcile findings and ascertain clinical applicability. Future investigations should also examine potential associations between EOC tumor, gut, and vaginal microbiota, patient symptoms throughout disease, chemotherapy response, recurrence, and survival.

Microbiota; Epithelial ovarian cancer

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2018 68: 394–424.

[2] Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runow-icz CD, et al. Ovarian cancer statistics, 2018. CA: a Cancer Journal for Clinicians. 2018 68: 284–296.

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a Cancer Journal for Clinicians. 2020; 70: 7–30.

[4] Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound in Obstetrics & Gynecology. 2018; 51: 293–303.

[5] Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. American Family Physician. 2016; 3: 937–944.

[6] Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial ovarian cancer: an overview. World Journal of Translational Medicine. 2014; 3: 1–8.

[7] Lisio M, Fu L, Goyeneche A, Gao Z, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Stand-points. International Journal of Molecular Sciences. 2019; 20: 952.

[8] Lee J, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019; 125: 4623–4629.

[9] Soong TR, Howitt BE, Miron A, Horowitz NS, Campbell F, Felt-mate CM, et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high‐grade serous carcinomas. Journal of Pathology. 2018; 246: 344–351.

[10] Kyo S, Ishikawa N, Nakamura K, Nakayama K. The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies. Cancer Medicine. 2020; 9: 421–431.

[11] Mota A, Triviño JC, Rojo-Sebastian A, Martínez-Ramírez Á, Chiva L, González-Martín A, et al. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. BMC Cancer. 2015; 15: 940.

[12] Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E. Ovarian Can-cers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines. 2018; 5: 16.

[13] Otsuka I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. International Journal of Molecular Sciences. 2021; 22: 4409.

[14] Lucidi A, Buca D, Ronsini C, Tinari S, Bologna G, Buca D, et al. Role of Extracellular Vesicles in Epithelial Ovarian Cancer: A Systematic Review. International Journal of Molecular Sciences. 2020; 21: 8762.

[15] Zhou Y, Zheng X, Xu B, Hu W, Huang T, Jiang J. The Identi-fication and Analysis of mRNA-lncRNA-miRNA Cliques From the Integrative Network of Ovarian Cancer. Frontiers in Genetics. 2019; 10: 751.

[16] Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012; 489: 250–256.

[17] Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, et al. The NIH Human Microbiome Project. Genome Research. 2009; 19: 2317–2323.

[18] Castaño-Rodríguez N, Goh K, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Scientific Reports. 2017; 7: 15957.

[19] Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, et al. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends in Cancer. 2020; 6: 86–97.

[20] Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, et al. The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers. 2019; 11: 459.

[21] Farolfi A, Gurioli G, Fugazzola P, Burgio SL, Casanova C, Ravaglia G, et al. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. International Journal of Molecular Sciences. 2019; 20: 2569.

[22] Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Scientific Reports. 2018; 8: 12394.

[23] Xie X, Yang M, Ding Y, Chen J. Microbial infection, inflammation and epithelial ovarian cancer. Oncology Letters. 2017; 14: 1911–1919.

[24] Piao J, Lee EJ, Lee M. Association between pelvic inflammatory disease and risk of ovarian cancer: an updated meta-analysis. Gynecologic Oncology. 2020; 157: 542–548.

[25] Idahl A, Le Cornet C, Gonzalez Maldonado S, Waterboer T, Ben-der N, Tjonneland A, et al. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. International Journal of Cancer. 2020; 147: 2042–2052.

[26] Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. European Journal of Clinical Microbiology & Infectious Diseases. 2012; 31: 2311–2317.

[27] Alibek K, Karatayeva N, Bekniyazov I. The role of infectious agents in urogenital cancers. Infectious Agents and Cancer. 2012; 7: 35.

[28] Fortner RT, Terry KL, Bender N, Brenner N, Hufnagel K, Butt J, et al. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses’ Health Studies. British Journal of Cancer. 2019; 120: 855–860.

[29] Idahl A, Lundin E, Elgh F, Jurstrand M, Møller JK, Marklund I, et al. Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. American Journal of Obstetrics and Gynecology. 2010; 202: 71.e1–71.e6.

[30] Ingerslev K, Høgdall E, Skovrider-Ruminski W, Schnack TH, Li-dang M, Høgdall C, et al. The prevalence of EBV and CMV DNA in epithelial ovarian cancer. Infectious Agents and Cancer. 2019; 14: 7.

[31] Jonsson S, Oda H, Lundin E, Olsson J, Idahl A. Chlamydia tra-chomatis, Chlamydial Heat Shock Protein 60 and Anti-Chlamydial Antibodies in Women with Epithelial Ovarian Tumors. Translational Oncology. 2018; 11: 546–551.

[32] Pathak S, Wilczynski JR, Paradowska E. Factors in Oncogenesis: Viral Infections in Ovarian Cancer. Cancers. 2020; 12: 561.

[33] Svahn MF, Faber MT, Christensen J, Norrild B, Kjaer SK. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. Acta Obstetricia et Gynecologica Scandinavica. 2014; 93: 6–19.

[34] Smith SB, Ravel J. The vaginal microbiota, host defence and repro-ductive physiology. Journal of Physiology. 2017; 595: 451–463.

[35] Muzny CA, Taylor CM, Swords WE, Tamhane A, Chattopadhyay D, Cerca N, et al. An Updated Conceptual Model on the Pathogen-esis of Bacterial Vaginosis. Journal of Infectious Diseases. 2019; 220: 1399–1405.

[36] Xu J, Peng JJ, Yang W, Fu K, Zhang Y. Vaginal microbiomes and ovarian cancer: a review. American Journal of Cancer Research. 2020; 10: 743–756.

[37] Chen C, Song X, Wei W, Zhong H, Dai J, Lan Z, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nature Communications. 2017; 8: 875.

[38] Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho C, et al. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers. 2019; 10: 433.

[39] Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005; 8: 19–32.

[40] Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation Science. 2010; 5: 69.

[41] Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. In Aromataris E, Munn Z (eds.) Joanna Briggs Institute Reviewer’s Manual. Australia: Joanna Briggs Institute. 2017.

[42] Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Medical Research Methodology. 2014; 14: 43.

[43] Paradowska E, Jabłońska A, Studzińska M, Wilczyński M, Wilczyński JR. Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. Scientific Reports. 2019; 9: 19935.

[44] Wang Q, Zhao L, Han L, Fu G, Tuo X, Ma S, et al. The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. Journal of Ovarian Research. 2020; 13: 8.

[45] Xu S, Liu Z, Lv M, Chen Y, Liu Y. Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer. Pathogens and Disease. 2019; 77: ftz019.

[46] Zhou B, Sun C, Huang J, Xia M, Guo E, Li N, et al. The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. Scientific Reports. 2019; 9: 1691.

[47] Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Alwine JC, et al. The ovarian cancer oncobiome. Oncotarget. 2017; 8: 36225–36245.

[48] Miao R, Badger TC, Groesch K, Diaz-Sylvester PL, Wilson T, Ghareeb A, et al. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer. PLoS ONE. 2020; 15: e0227707.

[49] Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 2015; 27: 27–40.

[50] Nené NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncology. 2019; 20: 1171–1182.

[51] Belizário JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Frontiers in Microbiology. 2015; 6: 1050.

[52] Diop K, Dufour J, Levasseur A, Fenollar F. Exhaustive repertoire of human vaginal microbiota. Human Microbiome Journal. 2019; 11: 100051.

[53] Johnson EL, Heaver SL, Walters WA, Ley RE. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes. Journal of Molecular Medicine. 2017; 95: 1–8.

[54] de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global bur-den of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health. 2020; 8: e180–e190.

[55] Li N, Zhan X. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4a3-mRNA axes. EPMA Journal. 2020; 11: 289–309.

[56] Zadora PK, Chumduri C, Imami K, Berger H, Mi Y, Selbach M, et al. Integrated Phosphoproteome and Transcriptome Analysis Reveals Chlamydia-Induced Epithelial-to-Mesenchymal Transition in Host Cells. Cell Reports. 2019; 26: 1286–1302.e8.

[57] Laban M, Ibrahim EA, Hassanin AS, Nasreldin MA, Mansour A, Khalaf WM, et al. Chlamydia trachomatis infection in primary fal-lopian tube and high-grade serous ovarian cancers: a pilot study. International Journal of Women’s Health. 2019; 11: 199–205.

[58] Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2020; 7: 14.

[59] Amabebe E, Anumba DOC. Female Gut and Genital Tract Microbiota-Induced Crosstalk and Differential Effects of Short-Chain Fatty Acids on Immune Sequelae. Frontiers in Immunology. 2020; 11: 2184.

[60] Davenport ER, Sanders JG, Song SJ, Amato KR, Clark AG, Knight R. The human microbiome in evolution. BMC Biology. 2017; 15: 127.

[61] Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nature Reviews. Gastroenterology & Hepatology. 2019; 16: 690–704.

[62] Xu K, Jiang B. Analysis of Mucosa-Associated Microbiota in Colorectal Cancer. Medical Science Monitor. 2017; 23: 4422–4430.

[63] Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, et al. Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis. Scientific Reports. 2018; 8: 10329.

[64] Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is asso-ciated with colorectal cancer. Frontiers in Microbiology. 2015; 6: 20.

[65] Raskov H, Burcharth J, Pommergaard H. Linking Gut Microbiota to Colorectal Cancer. Journal of Cancer. 2017; 8: 3378–3395.

[66] Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Research. 2014; 34: 1553–1561.

[67] Sumagin R, Parkos CA. Epithelial adhesion molecules and the regulation of intestinal homeostasis during neutrophil transepithelial migration. Tissue Barriers. 2015; 3: e969100.

[68] Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterology Research and Practice. 2012; 2012: 541842.

[69] Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Frontiers in Immunology. 2020; 11: 2192.

[70] Singh TP, Kaur G, Kapila S, Malik RK. Antagonistic Activity of Lactobacillus reuteri Strains on the Adhesion Characteristics of Selected Pathogens. Frontiers in Microbiology. 2017; 8: 486.

[71] Hokenstad AN, Mariani A, Walther-Antonio M. Vaginal detection of Porphyromonas somerae is indicative of endometrial cancer diagnosis. Gynecologic Oncology. 2017; 145: 76.

[72] Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenivas V. Association of Chlamydia trachomatis infection with human papillo-mavirus (HPV) & cervical intraepithelial neoplasia - a pilot study. Indian Journal of Medical Research. 2013; 137: 533–539.

[73] Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, et al. Cervicovaginal Fungi and Bacteria Associated with Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population. Frontiers in Microbiology. 2018; 9: 2533.

[74] Kwasniewski W, Wolun-Cholewa M, Kotarski J, Warchol W, Kuzma D, Kwasniewska A, et al. Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis. Oncology Letters. 2018; 16: 7035–7047.

[75] Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, et al. The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. Clinical Microbiology and Infection. 2015; 21: 674.e1–674.e9.

[76] Chao X, Sun T, Wang S, Fan Q, Shi H, Zhu L, et al. Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection. International Journal of Gynecologic Cancer. 2019; 29: 28–34.

[77] Cherif S, Amine A, Thies S, Taube ET, Braicu EI, Sehouli J, et al. Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases. 2021. (in press)

[78] Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. International Journal of Cancer. 2012; 131: 2349–2359.

[79] Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infectious Diseases. 2018; 18: 198–206.

[80] Pasquereau S, Al Moussawi F, Karam W, Diab Assaf M, Kumar A, Herbein G. Cytomegalovirus, Macrophages and Breast Cancer. Open Virology Journal. 2017; 11: 15–27.

[81] Yin M, Chen A, Zhao F, Ji X, Li C, Wang G. Detection of human cytomegalovirus in patients with epithelial ovarian cancer and its impacts on survival. Infectious Agents and Cancer. 2020; 15: 23.

[82] Verhoef J, van Kessel K, Snippe H. Immune Response in Human Pathology: Infections Caused by Bacteria, Viruses, Fungi, and Parasites. Nijkamp and Parnham’s Principles of Immunopharmacology. 2019; 360: 165–178.

[83] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology. 2014; 15: 178–196.

[84] Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012; 59: 228–236.

[85] Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factoralpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Research. 2007; 67: 585–592.

[86] Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2017; 167: 1125–1136.e8.

[87] Tahamtan A, Teymoori-Rad M, Nakstad B, Salimi V. Anti-Inflammatory MicroRNAs and their Potential for Inflammatory Diseases Treatment. Frontiers in Immunology. 2018; 9: 1377.

[88] Pedroza-Torres A, Romero-Cordoba SL, Justo-Garrido M, Salido-Guadarrama I, Rodriguez-Bautista R, Montano S, et al. MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities. Frontiers in Oncology. 2019; 9: 1404.

[89] Allegra A, Musolino C, Tonacci A, Pioggia G, Gangemi S. Interac-tions between the MicroRNAs and Microbiota in Cancer Development: Roles and Therapeutic Opportunities. Cancers. 2020; 12: 805.

[90] Muls A, Andreyev J, Lalondrelle S, Taylor A, Norton C, Hart A. Systematic Review: the Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women with a Gynecological Malig-nancy. International Journal of Gynecological Cancer. 2017; 27: 1550–1559.

[91] Rizzo AE, Gordon JC, Berard AR, Burgener AD, Avril S. The Fe-male Reproductive Tract Microbiome-Implications for Gynecologic Cancers and Personalized Medicine. Journal of Personalized Medicine. 2021; 11: 546.

[92] Tong J, Zhang X, Fan Y, Chen L, Ma X, Yu H, et al. Changes of Intestinal Microbiota in Ovarian Cancer Patients Treated with Surgery and Chemotherapy. Cancer Management and Research. 2020; 12: 8125–8135.

[93] Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Communications Biology. 2021; 4: 237.

[94] Garajová I, Balsano R, Wang H, Leonardi F, Giovannetti E, Deng D, et al. The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Review of Anticancer Therapy. 2021; 21: 165–176.

[95] Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut Microbiota Shapes the Efficiency of Cancer Therapy. Frontiers in Microbiology. 2019; 10: 1050.

[96] Gagliardi A, Totino V, Cacciotti F, Iebba V, Neroni B, Bonfiglio G, et al. Rebuilding the Gut Microbiota Ecosystem. International Journal of Environmental Research and Public Health. 2018; 15: 1679.

[97] Sehrawat N, Yadav M, Singh M, Kumar V, Sharma VR, Sharma AK. Probiotics in microbiome ecological balance providing a therapeutic window against cancer. Seminars in Cancer Biology. 2021; 70: 24–36.

[98] Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine. 2021; 13: 107.

[99] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer im-munotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020; 20: 651–668.

[100] Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. OncoTargets and Therapy. 2020; 13: 6109–6129.

[101] Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: are we there yet? Current Treatment Options in Oncology. 2017; 18: 59.

[102] Shaikh FY, Gills JJ, Sears CL. Impact of the microbiome on check-point inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine. 2019; 48: 642–647.

[103] Stancu AL. Gut Microbiome and the Response to Immunotherapy in Cancer. Discoveries. 2018; 6: e84.

[104] Gharaibeh RZ, Jobin C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut. 2019; 68: 385–388.

[105] Lee Y, van Nostrand JD, Tu Q, Lu Z, Cheng L, Yuan T, et al. The PathoChip, a functional gene array for assessing pathogenic properties of diverse microbial communities. ISME Journal. 2014; 7: 1973–1984.

[106] Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Had-field J, et al. Systematic comparison of microarray profiling, realtime PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010; 16: 991–1006.